CAR-Immunotherapy Companies

For each company:

• Company name
• Link to company website if available
• Country of origin
• Phase of development (preclinical or clinical)
• Type of cell products
• Cell donor type - Auto/Allo
• Key partner or licensee/licensor

Inclusions: All companies worldwide with CAR-Immunotherapy assets or programs (wholly owned, licensed or co-developed) in any stage of development (from preclinical to commercial).

Exclusions: Database does not contain information about vendors to CAR companies (manufacturers of reagents, materials, and devices) or service providers.

Updates from Nov. 2020 to April 2022:

• 292 companies total
• 55 companies added
• 1 company removed
• 9 changes in company name/website
• 44 changes to key partners/licensee/licensor
• 21 changes in type of cells developed
• 9 changes to donor type
• 13 updates to phase of development
• 4 changes to country of origin

This pie chart image dates from January 2020

• 203 companies total
• 25 companies added
• 4 companies were removed (due to mergers/acquisitions)
• 16 changes in company name/website
• 18 changes to key partners/licensee/licensor
• 16 changes in type of cells developed
• 2 updates to phase of development

Updates from Jan 2019 to Aug 2019:

• 187 companies total
• 20 companies added (including 10 from China)
• 1 company removed (Vor BioPharma - no CAR cell assets in development as was claimed previously)
• 2 companies changed name (Toolgen merged with Genexine, Conckwest/Nantkwest re-branded to ImmunityBio)
• 4 changes to key partners/licensee/licensor
• 1 update to phase of development
• 3 changes in type of cells developed

Updates from Aug 2018 to Jan 2019:

• 168 companies total
• 19 companies added
• 1 company removed (Novartis acquired Endocyte)
• 6 changes to key partners/licensee/licensor
• 3 update to phase of development

Original file posted Aug 2018: 150 companies (63 in China and 87 in other countries).